Udvalget fandt grund til betænkelighed ved, at hovedundersøgelsen omfattede en række patienter, som kunne have fået intensiv kemoterapi, og at dette kan have fået virkningen af Evoltra til at se mere lovende ud.
The Committee was concerned that the main study included a number of patients who could have been suitable for intensive chemotherapy and this could have made the effectiveness of Evoltra look more promising.